We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Abzena | LSE:ABZA | London | Ordinary Share | GB00BN65QN46 | ORD GBP0.002 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.75 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 15.75 | GBX |
Abzena (ABZA) Share Charts1 Year Abzena Chart |
|
1 Month Abzena Chart |
Intraday Abzena Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/8/2018 | 10:08 | Abzena PLC -development of biopharmaceutical products | 199 |
| 10/6/2018 | 02:48 | Abzena (ABZA) One to Watch on Monday | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 16/8/2018 08:28 by escapetohome escapetohome - 18 Jun 2018 - 19:40:43 - 184 of 197 Abzena PLC -development of biopharmaceutical products - ABZARumoured to be a bid target, buy the whole lot for less than recent fundraising and get the state of the art lab and production facility for free !! Roll up folks , company for sale!!!! |
Posted at 10/6/2018 02:48 by danieldanj Abzena (ABZA) Earnings-Reaction to Keep an Eye |
Posted at 17/11/2017 08:57 by qs99 some buying appearing again...a frustrating share! |
Posted at 17/9/2017 13:59 by knowbodyyouno Yes, it's somewhat derailed my expectations for this share - at least in the near term. Quite surprising really given all the recent II buy-ins. Still holding, but I think it'll be a fairly long turn around, to be honest.GLA |
Posted at 15/9/2017 09:23 by qs99 well that isn't very clever is it?! blimey....well holding with gritted teeth, and we will have to wait IMO for some of the "inside" hopefully to make good to provide the real catalyst now for short-term share growth....let's hope management can sort this out asap! |
Posted at 12/6/2017 10:03 by qs99 nope, but brokers seem upbeat and share price has chugged along nicely, so fingers Xd! |
Posted at 25/5/2017 10:28 by qs99 5m traded, blimey that is big volume, no price movement tho |
Posted at 23/1/2017 22:03 by qs99 well N+1 Singer who IMO are a decent outfit have a 93p intrinsic value DYOR and talk of further upside or as they put it the value would "increase substantially" as the partnered pipeline of Abzena inside programmes progress through clinical trial.....and from what I can see they are not expecting any cash call in the near term....DYOR as I say but just because My RF doesn't like this, does not mean he is correct....of course there are risks, as the RNS before Xmas showed when one of the programmes didn't progress, but that is the whole point of continuing to fill the "hopper" IMO so that on a portfolio basis they should IMO have more successes or at least enough that provides material upside to the current share price.GLA |
Posted at 21/1/2017 10:57 by status epilepticus RecordzNo, it definitely will not be over one year. The $ figure given in the RNS points to what may be achieved if certain milestones are reached. Of course that does not always happen. These type of agreements are staged payment agreements in which payments are triggered as per various targets set out in the agreement. These agreements reach far into the future so you're looking at large income streams that may only materialise in 5-7 years time for example Of course the agreement signed one must assume does validate the ABZA technology (ie, it works and it's commercial which is the most important thing) A great company though with a real edge. Could be a giant in the making in a few years time |
Posted at 20/1/2017 07:41 by 22richyrich On initial read of rns sounds positive $300million potential income..but then looked at share price last 12 months and fact this deal at lower value was announced 10 months ago and realised it's a classic loss making aim jam tomorrow story |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
